MOLECULAR BASIS OF ANTIGENIC SPECIFICITY
抗原特异性的分子基础
基本信息
- 批准号:2062022
- 负责人:
- 金额:$ 15.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1986
- 资助国家:美国
- 起止时间:1986-06-01 至 1995-06-30
- 项目状态:已结题
- 来源:
- 关键词:X ray crystallography antibody specificity antigen antibody reaction autoantibody calorimetry chemical binding computer simulation enzyme linked immunosorbent assay epitope mapping fluoresceins fluorescent dye /probe haptens hybridomas immunoglobulin structure immunoglobulins infrared spectrometry interferometry isomorphous substitution laboratory mouse molecular dynamics monoclonal antibody nuclear magnetic resonance spectroscopy peptide chemical synthesis protein sequence protein structure function solutions synthetic antigens systemic lupus erythematosus thermodynamics
项目摘要
Preliminary thermodynamic studies of a high affinity monoclonal
anti-fluorescyl antibody (4-4-20) indicate that its active site is a
shallow hydrophobic pocket, which binds fluorescein primarily through
entropy. Moreover, high resolution diffraction data (2.5 Angstrom) is
available for the liganded antigen binding fragment (Fab) of this antibody,
which crystallizes in 16% polyethyleneglycol. Liganded Fab fragments also
crystallize in a less polar solvent system (46.7%
2-methyl-2,4-pentanediol). The affinity of the intact IgG molecule is
300-fold lower in this solvent. Correlated crystal and solution studies of
both crystal systems are planned. With this information we hope to explain
the molecular basis of antigen binding to this antibody. Crystallization
trials are currently in progress with four other monoclonal anti-fluorescyl
antibodies which are idiotypically related to 4-4-20, but exhibit
affinities which vary over a 1000-fold range. Solution studies are planned
to determine whether the entropy predominance and active site
characteristics of 4-4-20 are common to the other clones as well.
Idiotypic determinants are generally thought to be located at or near the
active site. Crystal studies should clarify the nature of idiotypic
determinants and whether idiotypic reagents are valid tools for identifying
related active sites.
High resolution diffraction data (2.0 Angstrom) is available for the
unliganded Fab fragment of a monoclonal antibody which binds single
stranded DNA (BV04-01). In solution, the protein exhibited a base
specificity for pyrimidines, with greater affinity for thymine than
uracil. This antibody is of clinical importance because it was isolated
from a mouse with an autoimmune syndrome similar to systemic lupus
erythematosus. We have obtained a low-resolution (6 Angstrom) structure
and plan to extend this solution to higher resolution. We also plan to
perfuse oligonucleotides into crystals to determine the molecular basis of
the observed pyrimidine specificity.
高亲和力单克隆抗体的初步热力学研究
抗荧光抗体(4-4-20)表明其活性位点是一个
浅疏水口袋,主要通过
熵 此外,高分辨率衍射数据(2.5埃)是
可用于该抗体的配体化抗原结合片段(Fab),
其在16%聚乙二醇中结晶。 配体Fab片段还
在极性较小的溶剂体系中结晶(46.7%),
2-甲基-2,4-戊二醇)。 完整IgG分子的亲和力为
300-在这种溶剂中会降低一倍 相关晶体和溶液研究
两个水晶系统都在计划中。 我们希望通过这些信息来解释
抗原与抗体结合的分子基础 结晶
目前正在进行其他四种单克隆抗荧光素抗体的试验。
与4-4-20独特相关的抗体,但表现出
其亲和力在1000倍范围内变化。 计划进行解决方案研究
来确定熵优势和活性位点
4-4-20的特征对于其它克隆也是共同的。
独特型决定因素通常被认为位于或接近
活性部位 晶体研究应阐明独特型的性质
决定因素和独特型试剂是否是有效的工具,
相关的活跃网站
高分辨率衍射数据(2.0埃)可用于
单克隆抗体的未配体Fab片段,其结合单个
链DNA(BV 04 -01)。 在溶液中,该蛋白质显示出一种碱,
对嘧啶的特异性,对胸腺嘧啶的亲和力大于
尿嘧啶。 这种抗体具有临床重要性,因为它是分离出来的,
来自一只患有类似系统性狼疮的自身免疫综合征的老鼠
红斑 我们已经获得了低分辨率(6埃)结构
并计划将该解决方案扩展到更高的分辨率。 我们还计划
将寡核苷酸灌注到晶体中以确定
观察到的嘧啶特异性。
项目成果
期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Application of fluorescence spectroscopy for determining the structure and function of proteins.
- DOI:10.1007/978-1-4899-1079-0_1
- 发表时间:1995
- 期刊:
- 影响因子:0
- 作者:W. Jiskoot;V. Hlady;J. Naleway;J. Herron
- 通讯作者:W. Jiskoot;V. Hlady;J. Naleway;J. Herron
Molecular dynamics of the anti-fluorescein 4-4-20 antigen-binding fragment. 2. Time-resolved fluorescence spectroscopy.
抗荧光素 4-4-20 抗原结合片段的分子动力学。
- DOI:10.1021/bi00021a009
- 发表时间:1995
- 期刊:
- 影响因子:2.9
- 作者:Lim,K;Jameson,DM;Gentry,CA;Herron,JN
- 通讯作者:Herron,JN
Preparation and application of a fluorescein-labeled peptide for determining the affinity constant of a monoclonal antibody-hapten complex by fluorescence polarization.
- DOI:10.1016/0003-2697(91)90488-f
- 发表时间:1991-08
- 期刊:
- 影响因子:2.9
- 作者:W. Jiskoot;P. Hoogerhout;E. Beuvery;J. Herron;D. Crommelin
- 通讯作者:W. Jiskoot;P. Hoogerhout;E. Beuvery;J. Herron;D. Crommelin
Bifluorophoric molecules as fluorescent beacons for antibody-antigen binding.
双荧光分子作为抗体-抗原结合的荧光信标。
- DOI:10.1002/jmr.593
- 发表时间:2002
- 期刊:
- 影响因子:0
- 作者:Wei,Ai-Ping;Herron,JamesN
- 通讯作者:Herron,JamesN
Use of synthetic peptides as tracer antigens in fluorescence polarization immunoassays of high molecular weight analytes.
在高分子量分析物的荧光偏振免疫测定中使用合成肽作为示踪抗原。
- DOI:10.1021/ac00071a007
- 发表时间:1993
- 期刊:
- 影响因子:7.4
- 作者:Wei,AP;Herron,JN
- 通讯作者:Herron,JN
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JINDRICH H. KOPECEK其他文献
JINDRICH H. KOPECEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JINDRICH H. KOPECEK', 18)}}的其他基金
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
- 批准号:
8291234 - 财政年份:2011
- 资助金额:
$ 15.69万 - 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
- 批准号:
8645644 - 财政年份:2011
- 资助金额:
$ 15.69万 - 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
- 批准号:
8457100 - 财政年份:2011
- 资助金额:
$ 15.69万 - 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
- 批准号:
8021749 - 财政年份:2011
- 资助金额:
$ 15.69万 - 项目类别:
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer
用于治疗卵巢癌的主链可降解聚合物-药物缀合物
- 批准号:
8921139 - 财政年份:2011
- 资助金额:
$ 15.69万 - 项目类别:
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer
用于治疗卵巢癌的主链可降解聚合物-药物缀合物
- 批准号:
8779604 - 财政年份:2011
- 资助金额:
$ 15.69万 - 项目类别:
相似海外基金
Optimising antibody specificity and efficacy through Fc engineering
通过 Fc 工程优化抗体特异性和功效
- 批准号:
BB/N503927/1 - 财政年份:2015
- 资助金额:
$ 15.69万 - 项目类别:
Training Grant
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
7994664 - 财政年份:2010
- 资助金额:
$ 15.69万 - 项目类别:
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
8136201 - 财政年份:2010
- 资助金额:
$ 15.69万 - 项目类别:
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
8324720 - 财政年份:2010
- 资助金额:
$ 15.69万 - 项目类别:
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
8537214 - 财政年份:2010
- 资助金额:
$ 15.69万 - 项目类别:
Integrating Experiment and Theory to Characterize Diagnostic Antibody Specificity
结合实验和理论来表征诊断抗体特异性
- 批准号:
8328875 - 财政年份:2010
- 资助金额:
$ 15.69万 - 项目类别:
Quantitative Serum Antibody Specificity Screening in Celiac Disease
乳糜泻血清抗体特异性定量筛查
- 批准号:
7531456 - 财政年份:2008
- 资助金额:
$ 15.69万 - 项目类别:
Quantitative Serum Antibody Specificity Screening in Celiac Disease
乳糜泻血清抗体特异性定量筛查
- 批准号:
7673756 - 财政年份:2008
- 资助金额:
$ 15.69万 - 项目类别:
CARBOHYDRATES AND GLYCOPROTEINS IN ANTIBODY SPECIFICITY AND EFFECTOR MECHANISMS
抗体特异性和效应机制中的碳水化合物和糖蛋白
- 批准号:
6978238 - 财政年份:2004
- 资助金额:
$ 15.69万 - 项目类别:
HLA-D antigens, T cell epitopes and antibody specificity in SLE
SLE 中的 HLA-D 抗原、T 细胞表位和抗体特异性
- 批准号:
6663942 - 财政年份:2002
- 资助金额:
$ 15.69万 - 项目类别: